https://www.genengnews.com/gen-news-highlights/fda-approves-first-gene-therapy-for-inherited-disease/81255291/?utm_medium=newsletter&utm_source=gen+daily+news+highlights&utm_content=01&utm_campaign=gen+daily+news+highlights_20171220
December 20, 2017
FDA approved Spark Therapeutics’ gene therapy Luxturna™ (voretigene neparvovec-rzyl) for treating children and adults with the rare inherited blindness disorder biallelic RPE65 mutation-associated retinal dystrophy. Approval of the one-time adeno-associated virus vector (AAV)-delivered gene therapy, which FDA Commissioner Scott Gottlieb, M.D., described in a statement as “a milestone that reinforces the potential of this breakthrough approach in treating a wide-range of challenging disease,” marks the first gene therapy approval for a genetic disease. Spark has not confirmed the cost of treatment, although some commentators are anticipating a $1 million per patient price tag. Luxturna is currently under review by the European Medicines Agency.
FDA clearance of Luxturna marks the third approval by the agency for a gene therapy, but the first for an AAV-based treatment. In August this year, the U.S. regulator cleared Novartis’ cell-based chimeric antigen receptor T-cell (CAR-T) gene therapy Kymriah™ (tisagenlecleucel) for treating refractory or relapsed B-cell acute lymphoblastic leukemia. In October, Kite Pharma’s CAR-T therapy Yescarta™ (axicabtagene ciloleucel) was given the FDA nod for treating refractory or relapsed diffuse large B-cell lymphoma.
Administered as a subretinal injection, Luxturna uses an AAV vector to deliver a normal copy of the RPE65 gene to viable retinal cells in patients with confirmed disease. The gene therapy has been tested in two open-label Phase I studies and one open-label, controlled Phase III study, involving 41 participants aged four to 44 years at the time of treatment.
Luxturna will be administered to patients with genetically confirmed disease, by specially trained surgeons at selected centers in the U.S. Spark anticipates that the gene therapy will be available during the first quarter of 2018. The firm will manufacture Luxturna at its facility in West Philadelphia, which it says is the first manufacturing facility in the U.S. licensed for a gene therapy to treat an inherited disease.
“During the more than 12 years of innovative research with dedicated collaborators near and far, I’ve witnessed the dramatic improvement in vision in many patients who would have otherwise lost their sight,” commented Jean Bennett, M.D. Ph.D., the F.M. Kirby Professor of Ophthalmology in the Perelman School of Medicine at the University of Pennsylvania and Penn’s Scheie Eye Institute. “I believe that the success of the Luxturna clinical development program will pave the way for the development of other gene therapies that may help the millions of patients with genetic diseases who currently have limited or no treatment options.”
“This approval is a watershed milestone,” added Benjamin Yerxa, Ph.D., CEO at the Foundation Fighting Blindness (FFB), a nonprofit organization focused on research for preventing and treating blindness caused by inherited retinal diseases. “For people with an inherited retinal disease and for other patient communities, this decision may create important momentum for investigational gene therapies."
|
|
